Why the study?
Does four cycles of docetaxel with cyclophosphamide improve overall survival and disease-free survival compared to doxorubicin and cyclophosphamide?
Population
Older and younger patients
Comparison
Four cycles of TC vs Standard AC (doxorubicin and cyclophosphamide)
Design
RCT
Follow-up
7 years
Authors
Loading...
Supports TC over AC for adjuvant breast cancer therapy; extends prior DFS results to include OS benefit.
Does four cycles of docetaxel with cyclophosphamide improve overall survival and disease-free survival compared to doxorubicin and cyclophosphamide?
At 7-year follow-up, docetaxel with cyclophosphamide provides a survival benefit over standard doxorubicin and cyclophosphamide.
Jones et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: